PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.
2 reports, 0 independent
Updated Jul 8
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Fund held Vertex Pharmaceuticals stock in its portfolio.
- Janus Henderson Venture Fund holds Vertex stock, anticipating benefits from Trump-era tariffs.
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.
- Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.
- Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
- Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet